Global Information
회사소개 | 문의

세계의 신경자극기기 시장 예측

Global Neurostimulation Device Market Forecast 2019-2027

리서치사 Inkwood Research
발행일 2019년 01월 상품 코드 530650
페이지 정보 영문 135 Pages
가격
US $ 2,500 ₩ 2,880,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,456,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,184,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 신경자극기기 시장 예측 Global Neurostimulation Device Market Forecast 2019-2027
발행일 : 2019년 01월 페이지 정보 : 영문 135 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

세계의 신경자극기기(Neurostimulation Device) 시장 전망에 대해 분석했으며, 시장의 기본 구조·배경 구조, 주요 성장 촉진·억제요인, 시장 전체 및 제품별·용도별·지역별 시장 동향 전망(향후 9년간), 현재 시장 매력도, 기업간 경쟁 동향, 주요 기업 개요 등의 정보를 전해드립니다.

제1장 분석 범위

제2장 분석 방법

제3장 주요 요약

제4장 시장 결정요인

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장이 해결해야 할 과제

제5장 시장 세분화

  • 기기별 시장 세분화(향후 9년간)
    • 척수자극기(SCS)
    • 뇌심부자극기(DBS)
    • 천수신경자극기(SNS)
    • 미주신경자극기(VNS)
    • 기타
  • 용도별 시장 세분화(향후 9년간)
    • 통증 관리
    • 간질
    • 본태성진전
    • 요실금·변실금
    • 우울증
    • 근육긴장이상
    • 위마비
    • 파킨슨병

제6장 주요 지표

  • Porter's Five Forces 분석
  • 추정 분석
    • 정신질환 유병자수 증가
    • 세계 각국에서의 의료비 확대
    • 고령자 인구 증가
  • 밸류체인 분석
    • 의약품 관련 : 제조업체, 유통업체, 소매점포, 최종사용자
    • 의료기기 관련 : 제조업체, 유통업체, 최종사용자
  • 시장 기회 매트릭스
  • 벤더 구도

제7장 지역 분석

  • 북미(미국, 캐나다)
  • 유럽(영국, 프랑스, 독일, 스페인 등)
  • 아시아태평양(인도, 중국, 일본, 호주 등)
  • 기타 국가(RoW)

제8장 기업 개요

KSM 17.08.02

KEY FINDINGS

The global neurostimulation device market which was worth $XX million in 2018 is anticipated to grow at a CAGR of 10.01% during the forecast period of 2019-2027. Its net worth is estimated to rise to $XX million by the end of 2027. The fact that these devices aid in the therapeutic activation for many neurological diseases is majorly driving the market. Other factors include the high occurrence of diseases, second-line of treatment, increased elderly populace and the various developments in technology.

MARKET INSIGHTS

The global neurostimulation device market can be segmented by the type of system and by the application type. The different type of systems can be classified as Global DBS system market, Global SCS system market, Global SNS system market, Global VNS system market and others. The application of the neurostimulation devices can be seen in Depression market, Pain management market, Essential tremor market, Epilepsy market, Urinary and fecal incontinence market, Dystonia market, Gastroparesis market and in Parkinson's disease market. Albeit such a wide range of applications, safety concerns remain to be one of the major market challenges. Patients might be at risk of contracting infections at the time of implantation or may face issues if they are in contact with or near to electromagnetic radiation and electrical and gas-powered appliances. Also, the malfunction of the implanted device might go unnoticed by the patient leading to higher risks.

REGIONAL INSIGHTS

Geographically, the market can be divided into four major regions, namely, North America, Asia Pacific, Europe and the Rest of the World. The Asia-Pacific market is predicted to show the fastest growth over the forecast period. Factors like a large patient base and the rising investments in healthcare sectors in countries like China and Japan are proving conducive to the market growth in this region. At present, however, the North America region is leading the market scene. The United States is a major revenue contributor to the global neurostimulation device market. The North American region is expected to continue this dominance and hold the highest share by 2025 in the global market. The market is wildly attracting investors from all over the globe because of profitable aspects like advances in technology and the US government's increased focus on improving patient safety and procedure efficiency by using neurostimulation devices.

COMPETITIVE INSIGHTS

St. Jude Medical is a global medical device manufacturer that develops medical technology, products, and services for the treatment of neurological, chronic pain, and cardiac patients. Another company, Boston Scientific caters to high-quality medical devices used in the treatment of a large number of medical conditions. Medtronic Inc. manufactures and sells device-centered medicinal treatments globally along with assembling intra-operative imaging systems and image-guided surgery. It also offers web-based therapy management software solutions. The other major players in the market are Cogentix Medical Inc., St. Jude Medical Inc. (acquired by Abbott Laboratories), Aleva Neurotherapeutics SA, Boston Scientific Corporation, Helius Medical Technologies, The Magstim Company Limited, Cyberonics Inc., Neuronetics Inc., Depuy Synthes Companies, Ekso Bionics Holding Inc., Medtronic PLC, Dr. Langer Medical GmBH, Ectron Limited, Nevro Corp. and Hocoma AG

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. SPINAL CORD STIMULATORS HOLDS THE LARGEST MARKET SHARE IN TERMS OF NEUROSTIMULATION SYSTEM
    • 3.2.2. PAIN MANAGEMENT IS THE MAJORLY USED NEUROSTIMULATION APPLICATION

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. HIGH OCCURRENCE OF NEURO DISEASES
    • 4.2.2. DEVELOPMENTS IN TECHNOLOGY
    • 4.2.3. RISING DEMAND FOR MINIMALLY INVASIVE SURGERIES
    • 4.2.4. HIGH MARKET POTENTIAL FOR SCS DEVICES IN NEUROSTIMULATION
    • 4.2.5. INCREASING GERIATRIC POPULATION
    • 4.2.6. FAVORABLE REIMBURSEMENT AND INSURANCE APPROVAL POLICIES
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. HIGH PRICE OF NEUROMODULATION TREATMENT
    • 4.3.2. SIDE EFFECTS OF ASSOCIATED NEUROSTIMULATION DEVICES
    • 4.3.3. ANONYMOUS APPLIANCE OF SCS THERAPY
    • 4.3.4. STRINGENT REGULATORY APPROVALS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. DEVELOPMENT OF INDICATION FOR SCS
    • 4.4.2. INCREASING THE DEMAND FOR NEUROSTIMULATION DEVICES WITHSTANDING MRI SCANS
    • 4.4.3. GROWING OCCURRENCE OF CHRONIC DISCOMFORT
  • 4.5. MARKET CHALLENGES
    • 4.5.1. OBTAINABILITY OF ALTERNATIVE THERAPY
    • 4.5.2. SAFETY CONCERNS

5. MARKET BY SYSTEM

  • 5.1. SPINAL CORD STIMULATORS (SCS)
  • 5.2. DEEP BRAIN STIMULATORS (DBS)
  • 5.3. SACRAL NERVE STIMULATORS (SNS)
  • 5.4. VAGUS NERVE STIMULATORS (VNS)
  • 5.5. GASTRIC ELECTRIC STIMULATOR
  • 5.6. OTHER SYSTEM

6. MARKET BY APPLICATIONS

  • 6.1. PAIN MANAGEMENT
  • 6.2. EPILEPSY
  • 6.3. ESSENTIAL TREMOR
  • 6.4. URINARY AND FECAL INCONTINENCE
  • 6.5. DEPRESSION
  • 6.6. DYSTONIA
  • 6.7. GASTROPARESIS
  • 6.8. PARKINSON'S DISEASE
  • 6.9. OTHER APPLICATIONS

7. KEY ANALYTICS

  • 7.1. PORTER'S FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTES
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF RIVALRY
  • 7.2. ESTIMATION ANALYSIS
    • 7.2.1. INCREASING PREVALENCE OF MENTAL HEALTH PROBLEMS
    • 7.2.2. RISING HEALTHCARE EXPENDITURE ACROSS THE GLOBE
    • 7.2.3. RISING GERIATRIC POPULATION
  • 7.3. VALUE CHAIN ANALYSIS
  • 7.4. PESTLE ANALYSIS
  • 7.5. OPPORTUNITY MATRIX

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. THE UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. THE UNITED KINGDOM
    • 8.2.2. FRANCE
    • 8.2.3. GERMANY
    • 8.2.4. SPAIN
    • 8.2.5. ITALY
    • 8.2.6. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. INDIA
    • 8.3.2. CHINA
    • 8.3.3. JAPAN
    • 8.3.4. AUSTRALIA
    • 8.3.5. SOUTH KOREA
    • 8.3.6. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST AND AFRICA

9. COMPETITIVE LANDSCAPE

  • 9.1. MARKET SHARE ANALYSIS
  • 9.2. COMPANY PROFILES
    • 9.2.1. ALEVA NEUROTHERAPEUTICS SA
      • 9.2.1.1. OVERVIEW
      • 9.2.1.2. PRODUCT PORTFOLIO
      • 9.2.1.3. SCOT ANALYSIS
      • 9.2.1.4. STRATEGIC INITIATIVES
    • 9.2.2. BOSTON SCIENTIFIC CORPORATION
      • 9.2.2.1. OVERVIEW
      • 9.2.2.2. PRODUCT PORTFOLIO
      • 9.2.2.3. SCOT ANALYSIS
      • 9.2.2.4. STRATEGIC INITIATIVES
    • 9.2.3. COGENTIX MEDICAL INC.
      • 9.2.3.1. OVERVIEW
      • 9.2.3.2. PRODUCT PORTFOLIO
      • 9.2.3.3. SCOT ANALYSIS
      • 9.2.3.4. STRATEGIC INITIATIVES
    • 9.2.4. CYBERONICS INC.
      • 9.2.4.1. OVERVIEW
      • 9.2.4.2. PRODUCT PORTFOLIO
      • 9.2.4.3. SCOT ANALYSIS
      • 9.2.4.4. STRATEGIC INITIATIVES
    • 9.2.5. DEPUY SYNTHES COMPANIES
      • 9.2.5.1. OVERVIEW
      • 9.2.5.2. PRODUCT PORTFOLIO
      • 9.2.5.3. SCOT ANALYSIS
      • 9.2.5.4. STRATEGIC INITIATIVES
    • 9.2.6. DR. LANGER MEDICAL GMBH
      • 9.2.6.1. OVERVIEW
      • 9.2.6.2. PRODUCT PORTFOLIO
      • 9.2.6.3. SCOT ANALYSIS
      • 9.2.6.4. STRATEGIC INITIATIVES
    • 9.2.7. ECTRON LIMITED
      • 9.2.7.1. OVERVIEW
      • 9.2.7.2. PRODUCT PORTFOLIO
      • 9.2.7.3. SCOT ANALYSIS
      • 9.2.7.4. STRATEGIC INITIATIVES
    • 9.2.8. EKSO BIONICS HOLDING INC.
      • 9.2.8.1. OVERVIEW
      • 9.2.8.2. PRODUCT PORTFOLIO
      • 9.2.8.3. SCOT ANALYSIS
      • 9.2.8.4. STRATEGIC INITIATIVES
    • 9.2.9. HELIUS MEDICAL TECHNOLOGIES
      • 9.2.9.1. OVERVIEW
      • 9.2.9.2. PRODUCT PORTFOLIO
      • 9.2.9.3. SCOT ANALYSIS
      • 9.2.9.4. STRATEGIC INITIATIVES
    • 9.2.10. HOCOMA AG
      • 9.2.10.1. OVERVIEW
      • 9.2.10.2. PRODUCT PORTFOLIO
      • 9.2.10.3. SCOT ANALYSIS
      • 9.2.10.4. STRATEGIC INITIATIVES
    • 9.2.11. MEDTRONIC PLC
      • 9.2.11.1. OVERVIEW
      • 9.2.11.2. PRODUCT PORTFOLIO
      • 9.2.11.3. SCOT ANALYSIS
      • 9.2.11.4. STRATEGIC INITIATIVES
    • 9.2.12. NEURONETICS INC.
      • 9.2.12.1. OVERVIEW
      • 9.2.12.2. PRODUCT PORTFOLIO
      • 9.2.12.3. SCOT ANALYSIS
      • 9.2.12.4. STRATEGIC INITIATIVES
    • 9.2.13. NEVRO CORP.
      • 9.2.13.1. OVERVIEW
      • 9.2.13.2. PRODUCT PORTFOLIO
      • 9.2.13.3. SCOT ANALYSIS
      • 9.2.13.4. STRATEGIC INITIATIVES
    • 9.2.14. ST. JUDE MEDICAL INC. (ACQUIRED BY ABBOTT LABORATORIES)
      • 9.2.14.1. OVERVIEW
      • 9.2.14.2. PRODUCT PORTFOLIO
      • 9.2.14.3. SCOT ANALYSIS
      • 9.2.14.4. STRATEGIC INITIATIVES
    • 9.2.15. THE MAGSTIM COMPANY LIMITED
      • 9.2.15.1. COMPANY OVERVIEW
      • 9.2.15.2. PRODUCT PORTFOLIO
      • 9.2.15.3. SCOT ANALYSIS
      • 9.2.15.4. STRATEGIC INITIATIVES

TABLE LIST

  • TABLE 1 GLOBAL NEUROSTIMULATION DEVICE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 2 GLOBAL NEUROSTIMULATION DEVICE MARKET BY SYSTEM 2019-2027 ($ MILLION)
  • TABLE 3 GLOBAL SPINAL CORD STIMULATORS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL DEEP BRAIN STIMULATORS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL SACRAL NERVE STIMULATORS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL VAGUS NERVE STIMULATORS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL GASTRIC ELECTRIC STIMULATOR MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL OTHER SYSTEM MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL NEUROSTIMULATION DEVICE MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL PAIN MANAGEMENT MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL EPILEPSY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL ESSENTIAL TREMOR MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL URINARY AND FECAL INCONTINENCE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL DEPRESSION MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL DYSTONIA MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL GASTROPARESIS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL PARKINSON'S DISEASE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 18 GLOBAL OTHER APPLICATIONS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 19 GLOBAL NEUROSTIMULATION DEVICE MARKET BY GEOGRAPHY 2019-2027, (IN $ BILLION)
  • TABLE 20 CONDITION TREATED BY NEUROSTIMULATION DEVICES IN THE UNITED STATES
  • TABLE 21 NORTH AMERICA NEUROSTIMULATION DEVICE MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 22 EUROPE NEUROSTIMULATION DEVICE MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 23 ASIA PACIFIC NEUROSTIMULATION DEVICE MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 24 REST OF WORLD NEUROSTIMULATION DEVICE MARKET BY COUNTRY 2019-2027 ($ MILLION)

FIGURES LIST

  • FIGURE 1 GLOBAL NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 GLOBAL NEUROSTIMULATION DEVICE MARKET SHARE BY SYSTEM 2018 & 2027 (%)
  • FIGURE 3 GLOBAL NEUROSTIMULATION DEVICE MARKET BY SPINAL CORD STIMULATORS 2019-2027 ($ MILLION)
  • FIGURE 4 GLOBAL NEUROSTIMULATION DEVICE MARKET BY DEEP BRAIN STIMULATORS 2019-2027 ($ MILLION)
  • FIGURE 5 GLOBAL NEUROSTIMULATION DEVICE MARKET BY SACRAL NERVE STIMULATORS 2019-2027 ($ MILLION)
  • FIGURE 6 GLOBAL NEUROSTIMULATION DEVICE MARKET BY VAGUS NERVE STIMULATORS 2019-2027 ($ MILLION)
  • FIGURE 7 GLOBAL NEUROSTIMULATION DEVICE MARKET BY GASTRIC ELECTRIC STIMULATOR 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL NEUROSTIMULATION DEVICE MARKET BY OTHER SYSTEM 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL NEUROSTIMULATION DEVICE MARKET SHARE BY APPLICATIONS 2018 & 2027 (%)
  • FIGURE 10 GLOBAL NEUROSTIMULATION DEVICE MARKET BY PAIN MANAGEMENT 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL NEUROSTIMULATION DEVICE MARKET BY EPILEPSY 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL NEUROSTIMULATION DEVICE MARKET BY ESSENTIAL TREMOR 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL NEUROSTIMULATION DEVICE MARKET BY URINARY AND FECAL INCONTINENCE 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL NEUROSTIMULATION DEVICE MARKET BY DEPRESSION 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL NEUROSTIMULATION DEVICE MARKET BY DYSTONIA 2019-2027 ($ MILLION)
  • FIGURE 16 GLOBAL NEUROSTIMULATION DEVICE MARKET BY GASTROPARESIS 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL NEUROSTIMULATION DEVICE MARKET BY PARKINSON'S DISEASE 2019-2027 ($ MILLION)
  • FIGURE 18 GLOBAL NEUROSTIMULATION DEVICE MARKET BY OTHER APPLICATIONS 2019-2027 ($ MILLION)
  • FIGURE 19 PORTER'S FIVE FORCE MODEL
  • FIGURE 20 PREVALENCE OF MENTAL HEALTH DISORDERS ACROSS THE GLOBE BETWEEN PERIOD 2012 AND 2020 (MILLION)
  • FIGURE 21 RISING GERIATRIC POPULATION ACROSS THE GLOBE FOR PERIOD 2014-2020 (MILLION)
  • FIGURE 22 VALUE CHAIN OF NEUROSTIMULATION DRUGS
  • FIGURE 23 THE UNITED STATES NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 24 CANADA NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 25 THE UNITED KINGDOM NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 26 FRANCE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 27 GERMANY NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 28 SPAIN NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 29 ITALY NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 REST OF EUROPE NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 INDIA NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 CHINA NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 33 JAPAN NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 34 AUSTRALIA NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 35 SOUTH KOREA NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 36 REST OF ASIA PACIFIC NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 37 LATIN AMERICA NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 38 MIDDLE EAST AND AFRICA NEUROSTIMULATION DEVICE MARKET 2019-2027 ($ MILLION)
  • FIGURE 39 NEUROSTIMULATION DEVICE COMPANY MARKET SHARE 2018 (%)
Back to Top
전화 문의
F A Q
 
BCC Research